Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.38 |
| ▸ | CA2 | P00918 | 7/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23792182 | 0.83 | TERT (0.35) | CA1CA2GRIA1P4HTMALDH1A1 | |
| SCHEMBL13366726 | 0.79 | GRIA1 (0.38) | CA1CA2GRIA1P4HTMALDH1A1 | |
| SCHEMBL20310027 | 0.78 | TP53 (0.36) | CA1CA2ALDH1A1 | |
| SCHEMBL21104354 | 0.76 | HDAC3 (0.44) | CA1CA2GRIA1ALDH1A1 | |
| SCHEMBL13672667 | 0.74 | CA1 (0.38) | CA1CA2GRIA1P4HTM | |
| SCHEMBL6846135 | 0.73 | — | — | |
| SCHEMBL18971082 | 0.72 | CA1 (0.35) | CA1CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31301878 | 0.71 | CA2 (0.40) | CA1CA2 | |
| SCHEMBL21872080 | 0.70 | P4HTM (0.41) | GRIA1P4HTM | |
| SCHEMBL208469 | 0.70 | GRIA1 (0.37) | CA2GRIA1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | CA1 4317/4885CA2 3669/4885GRIA1 3097/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | CA1 4317/4885CA2 3669/4885GRIA1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.